Epidermal growth factor receptor (EGFR) gene mutations are common in non-small cell lung cancer (NSCLC) patients characterized by female gender, a history of never smoking and an adenocarcinoma histology. These mutations usually predict favorable EGFR-tyrosine kinase inhibitors (TKIs) treatment efficacy and outcome. We report a non-smoking female with synchronous brain metastasis from pulmonary squamous cell carcinoma (SCC), which uncommonly harbored an EGFR exon 19 mutation and dramatically responded to EGFR TKI treatment. This case highlights that EGFR mutational analysis may be performed for pulmonary SCC patients that are East Asian females without a smoking history. The identification of EGFR mutations in pulmonary SCC may provide a treatment option using EGFR-TKIs.
|Number of pages||7|
|Publication status||Published - 2015|
- epidermal growth factor receptor (EGFR) mutation
- EGFR tyrosine kinase inhibitor (TKI)
- pulmonary squamous cell carcinoma